Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
Zacks Investment Research | Jun 11, 2019 09:03PM ET
Masimo Corporation (NASDAQ:MASI) recently announced that it has received FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients weighing less than 10 kg. This FDA nod will prove beneficial for the company as O3 Regional Oximetry uses near-infrared spectroscopy (NIRS) to enable monitoring of cerebral tissue oxygen saturation (rSO2) and will help in delivering accurate measurement pertaining to neonatal patients.
Notably, the FDA clearance will expand the O3 platform and the benefits of monitoring with O3 will now be accessible to patients of all ages – from neonates to adults.
Few Words About O3 Regional Oximetry
O3 Regional Oximetry — one of Masimo’s monitoring solutions — helps in monitoring cerebral oxygenation in cases wherein peripheral pulse oximetry alone might not be enough to fully indicate oxygen in the brain. The solution seamlessly integrates with the Root platform along with SedLine brain function monitoring, thereby delivering a more comprehensive brain monitoring solution.
With the usage of NIRS, the clinicians will be able to monitor rSO2 on both sides of the brain and this will be specifically helpful in offering an insight into neonatal patient status primarily because neonatal pathology is mostly brain-related.
Masimo’s Root Platform at a Glance
Notably, Masimo’s Root platform is a very powerful, expandable patient monitoring and connectivity hub that brings together a range of technologies, devices, and systems to offer multimodal monitoring and connectivity solutions in a single, clinician-centric platform.
O3 is available as a Masimo Open Connect (MOC-9) module for the Root Patient Monitoring and Connectivity Platform.
Root’s plug-and-play expansion capabilities help in simultaneous monitoring of O3 and other measurements like SET Measure-through Motion and Low Perfusion pulse oximetry.
Masimo: A Leading Player in Pulse Oximetry
Masimo is a global pioneer in the field of highly-advanced non-invasive monitoring technologies. The company’s flagship Signal Extraction Technology (SET) pulse oximetry or SET pulse oximeter solution successfully eliminates the limitations of conventional mediums. Masimo’s rainbow SET technology has been gaining traction driven by rapid product development.
Together with the proven benefits of Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, O3 can help clinicians get a far more expanded visibility of neonatal oxygenation status.
Patient Monitoring in Focus
Masimo is touted to be the most innovative company in the patient monitoring space. According to report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.